AcelRx Pharmaceutical's sufentanil sublingual tablet (DSUVIA) to be highlighted during a presentation at the Boswick Burn and Wound Symposium

Stock Information for AcelRx Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About AcelRx Pharmaceuticals Inc.

AcelRx Announces Rebranding With Name Change to Talphera, Inc.
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update
AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad(TM) Clinical Study
AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023
AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study
AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference
AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.